CY1113475T1 - Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεων - Google Patents
Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεωνInfo
- Publication number
- CY1113475T1 CY1113475T1 CY20121100940T CY121100940T CY1113475T1 CY 1113475 T1 CY1113475 T1 CY 1113475T1 CY 20121100940 T CY20121100940 T CY 20121100940T CY 121100940 T CY121100940 T CY 121100940T CY 1113475 T1 CY1113475 T1 CY 1113475T1
- Authority
- CY
- Cyprus
- Prior art keywords
- sodium
- arsenic
- treatment
- alkali metal
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
Η παρούσα αίτηση σχετίζεται με φαρμακευτικές συνθέσεις και μεθόδους για αγωγή ουρογενετικών παθήσεων και οστικής μετάστασης σε άνθρωπο, η οποία φαρμακευτική σύνθεση περιέχει αποτελεσματική ποσότητα μετά αλκαλιμετάλλου ή μετάλλου αλκαλικής γαίας άλατος αρσενικώδους οξέος και/ή φαρμακευτικά αποδεκτό πρόσθετο. Σύμφωνα με την παρούσα εφεύρεση, το μετά αλκαλιμετάλλου άλας αρσενικώδους οξέος είναι μετα-αρσενικώδες νάτριο (AsO2Na) ή μετα-αρσενικώδες κάλιο (ASO2K). Η αποτελεσματική ποσότητα του μετά αλκαλιμετάλλου ή μετάλλου αλκαλικής γαίας άλατος αρσενικώδους οξέος είναι 0.0001-1500 mg/kg, κατά προτίμηση 1-1000 mg/kg, κατά περαιτέρω προτίμηση 1-150 mg/kg, και κατά μέγιστη προτίμηση 50-100 mg/kg βάρους σώματος/ημέρα. Η μορφή χορήγησης των φαρμακευτικών συνθέσεων της εφεύρεσης είναι κατά προτίμηση από το στόμα, όπως δισκίο, καψάκιο, κόνις και/ή διάλυμα με φαρμακευτικά αποδεκτό φορέα, αραιωτή ή έκδοχο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05076071A EP1721615A1 (en) | 2005-05-09 | 2005-05-09 | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
EP06732912A EP1885380B1 (en) | 2005-05-09 | 2006-05-09 | Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113475T1 true CY1113475T1 (el) | 2016-06-22 |
Family
ID=35197739
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100940T CY1113475T1 (el) | 2005-05-09 | 2012-10-10 | Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεων |
CY20191101162T CY1122522T1 (el) | 2005-05-09 | 2019-11-06 | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191101162T CY1122522T1 (el) | 2005-05-09 | 2019-11-06 | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος |
Country Status (24)
Country | Link |
---|---|
US (2) | US20090011047A1 (el) |
EP (5) | EP1721615A1 (el) |
JP (1) | JP5026408B2 (el) |
KR (3) | KR20160035101A (el) |
CN (2) | CN101277707A (el) |
AR (1) | AR054448A1 (el) |
AU (1) | AU2006244767B2 (el) |
BR (1) | BRPI0608716A2 (el) |
CA (3) | CA2840609C (el) |
CY (2) | CY1113475T1 (el) |
DK (2) | DK1885380T3 (el) |
ES (2) | ES2394264T3 (el) |
HK (1) | HK1109736A1 (el) |
HU (1) | HUE046029T2 (el) |
IL (3) | IL187220A (el) |
LT (1) | LT3067068T (el) |
PL (2) | PL1885380T3 (el) |
PT (1) | PT1885380E (el) |
RU (1) | RU2401662C2 (el) |
SG (5) | SG10201405278SA (el) |
SI (2) | SI1885380T1 (el) |
TW (5) | TW201615200A (el) |
WO (1) | WO2006121280A1 (el) |
ZA (1) | ZA200710559B (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
US20120045520A1 (en) * | 2008-08-21 | 2012-02-23 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
TR201905548T4 (tr) * | 2009-09-10 | 2019-05-21 | Kominox Inc | Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. |
MX2012002922A (es) * | 2009-09-18 | 2012-09-07 | Kominox Inc | Metodos para tratar tumores del cerebro. |
WO2011086137A1 (en) * | 2010-01-13 | 2011-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Promyelocytic leukemia protein as a redox sensor |
WO2012095379A1 (en) * | 2011-01-11 | 2012-07-19 | Universität Basel | Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression |
WO2012131487A2 (en) * | 2011-03-30 | 2012-10-04 | Kominox, Inc. | Compositions and methods for the treatment of cancer |
KR101309844B1 (ko) * | 2013-03-15 | 2013-09-23 | 박상채 | 항암 활성 증진용 한약재 및 이의 제조방법 |
RU2618405C1 (ru) * | 2015-12-31 | 2017-05-03 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств |
US10806768B2 (en) * | 2016-05-26 | 2020-10-20 | Stephen N. Pitcher | Composition for promoting metallothionein production |
AU2017368444B9 (en) | 2016-12-01 | 2020-07-02 | Eupharma Pty Ltd | Arsenic compositions |
MA52088A (fr) * | 2018-03-22 | 2021-01-27 | Komipharm Int Australia Pty Ltd | Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication |
WO2019234112A1 (en) * | 2018-06-05 | 2019-12-12 | Katholieke Universiteit Leuven | Combination treatment of arsenic oxide and antiandrogens |
AU2021219576A1 (en) * | 2020-02-16 | 2022-09-15 | Komipharm International Australia Pty Ltd | Method of treatment using meta-arsenite |
KR20220020637A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물 |
KR20220020635A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 외용제 조성물 |
KR20220020633A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 주사제 조성물 |
CN112336746A (zh) * | 2020-10-23 | 2021-02-09 | 内蒙古科技大学包头医学院 | 一种膀胱癌灌注化疗药物及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
FR2431686A1 (fr) | 1978-07-20 | 1980-02-15 | Nestle Sa Soc Ass Tech Prod | Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
KR930001917A (ko) * | 1991-07-26 | 1993-02-22 | 김두석 | 악성 종양 치료제의 제조방법 |
DE69434093T2 (de) | 1994-02-18 | 2006-03-09 | Tamara Vasilievna Vorobieva | Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems |
CA2307208A1 (en) * | 1997-10-15 | 1999-04-22 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
ES2399480T3 (es) | 1997-11-10 | 2013-04-01 | Memorial Sloan-Kettering Cancer Center | Procedimiento de producción de formulaciones de trióxido de arsénico |
CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
CA2481602C (en) * | 2002-04-10 | 2011-06-21 | Korea Microbiological Laboratories, Ltd. | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
KR100632250B1 (ko) * | 2004-02-16 | 2006-10-11 | 정태호 | 비소 화합물을 유효성분으로 하는 항암제 |
US20060104292A1 (en) | 2004-11-15 | 2006-05-18 | Gupta Vivek G | System and methods for supporting multiple communications interfaces with single client interface |
EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
US20090246291A1 (en) | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
TR201905548T4 (tr) | 2009-09-10 | 2019-05-21 | Kominox Inc | Kanser kök hücresi hedefli ve ilaç dirençli kanser terapisi. |
-
2005
- 2005-05-09 EP EP05076071A patent/EP1721615A1/en not_active Withdrawn
-
2006
- 2006-05-09 SG SG10201405278SA patent/SG10201405278SA/en unknown
- 2006-05-09 EP EP11165670.8A patent/EP2361628A1/en not_active Ceased
- 2006-05-09 CA CA2840609A patent/CA2840609C/en active Active
- 2006-05-09 JP JP2008511051A patent/JP5026408B2/ja active Active
- 2006-05-09 HU HUE16162414A patent/HUE046029T2/hu unknown
- 2006-05-09 TW TW105102103A patent/TW201615200A/zh unknown
- 2006-05-09 PT PT06732912T patent/PT1885380E/pt unknown
- 2006-05-09 SI SI200631444T patent/SI1885380T1/sl unknown
- 2006-05-09 TW TW095116432A patent/TWI386214B/zh active
- 2006-05-09 ES ES06732912T patent/ES2394264T3/es active Active
- 2006-05-09 SG SG2011075330A patent/SG175633A1/en unknown
- 2006-05-09 BR BRPI0608716-7A patent/BRPI0608716A2/pt not_active Application Discontinuation
- 2006-05-09 CA CA2926846A patent/CA2926846C/en active Active
- 2006-05-09 RU RU2007145489/14A patent/RU2401662C2/ru active
- 2006-05-09 SG SG2012003091A patent/SG177983A1/en unknown
- 2006-05-09 LT LT16162414T patent/LT3067068T/lt unknown
- 2006-05-09 EP EP14166070.4A patent/EP2762145A1/en not_active Ceased
- 2006-05-09 ES ES16162414T patent/ES2754372T3/es active Active
- 2006-05-09 PL PL06732912T patent/PL1885380T3/pl unknown
- 2006-05-09 TW TW101132058A patent/TWI539957B/zh active
- 2006-05-09 CN CNA2006800250320A patent/CN101277707A/zh active Pending
- 2006-05-09 SG SG10202100785PA patent/SG10202100785PA/en unknown
- 2006-05-09 TW TW104124162A patent/TWI574692B/zh active
- 2006-05-09 DK DK06732912.8T patent/DK1885380T3/da active
- 2006-05-09 SI SI200632358T patent/SI3067068T1/sl unknown
- 2006-05-09 AR ARP060101851A patent/AR054448A1/es unknown
- 2006-05-09 PL PL16162414T patent/PL3067068T3/pl unknown
- 2006-05-09 KR KR1020167007395A patent/KR20160035101A/ko not_active Application Discontinuation
- 2006-05-09 CN CN201510064962.8A patent/CN104758312A/zh active Pending
- 2006-05-09 EP EP16162414.3A patent/EP3067068B1/en active Active
- 2006-05-09 EP EP06732912A patent/EP1885380B1/en active Active
- 2006-05-09 DK DK16162414T patent/DK3067068T3/da active
- 2006-05-09 CA CA2608035A patent/CA2608035C/en active Active
- 2006-05-09 SG SG10201602555WA patent/SG10201602555WA/en unknown
- 2006-05-09 TW TW103132530A patent/TWI522105B/zh active
- 2006-05-09 US US11/631,962 patent/US20090011047A1/en not_active Abandoned
- 2006-05-09 AU AU2006244767A patent/AU2006244767B2/en active Active
- 2006-05-09 KR KR1020077028751A patent/KR101413731B1/ko active IP Right Grant
- 2006-05-09 WO PCT/KR2006/001731 patent/WO2006121280A1/en active Application Filing
- 2006-05-09 KR KR1020157017831A patent/KR20150085122A/ko not_active Application Discontinuation
-
2007
- 2007-11-07 IL IL187220A patent/IL187220A/en active IP Right Grant
- 2007-12-04 ZA ZA200710559A patent/ZA200710559B/xx unknown
-
2008
- 2008-03-17 HK HK08103067.4A patent/HK1109736A1/xx unknown
-
2012
- 2012-10-10 CY CY20121100940T patent/CY1113475T1/el unknown
-
2013
- 2013-12-17 IL IL229975A patent/IL229975A/en active IP Right Grant
-
2016
- 2016-03-22 US US15/077,373 patent/US11464859B2/en active Active
- 2016-03-22 IL IL244728A patent/IL244728A0/en unknown
-
2019
- 2019-11-06 CY CY20191101162T patent/CY1122522T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113475T1 (el) | Μετα-αρσενικωδες νατριο για χρηση στην αγωγη μεταστατικων νεοπλασματικων παθησεων | |
CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
TW200637614A (en) | Bendamustine pharmaceutical compositions | |
MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
CY1106996T1 (el) | Δισκιο με υψηλο φορτιο φαρμακου | |
MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
TNSN03110A1 (en) | Azaindoles. | |
BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
NO20053398L (no) | Farmasoytiske preparater av sertaconazol for vaginal anvendelse. | |
IL187183A0 (en) | Pharmaceutical formulation of apomorphine for buccal administration | |
MY143549A (en) | Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases | |
MY175373A (en) | Crystal form of phenylamino pyrimidine derivatives | |
MXPA05008368A (es) | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. | |
AR069508A1 (es) | Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento | |
CO5390076A1 (es) | Composiciones farmaceuticas | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
PL1727817T3 (pl) | Pochodne azabicyklooktan-3-onu i ich zastosowanie | |
UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
TW200639156A (en) | New compounds | |
BR0311535A (pt) | Uso de cianopirrolidinas substituìdas e preparações de combinações contendo as mesmas para o tratamento da hiperlipidemia e doenças associadas | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
EA202192553A1 (ru) | Protac, расщепляющие рецептор эстрогена |